MARIA RODRIGUEZ-BARRADAS to Pneumococcal Vaccines
This is a "connection" page, showing publications MARIA RODRIGUEZ-BARRADAS has written about Pneumococcal Vaccines.
Connection Strength
2.751
-
Quantitative and Qualitative Antibody Responses to Immunization With the Pneumococcal Polysaccharide Vaccine in HIV-Infected Patients After Initiation of Antiretroviral Treatment: Results From a Randomized Clinical Trial. J Infect Dis. 2015 Jun 01; 211(11):1703-11.
Score: 0.434
-
The CAPITA study of protein-conjugate pneumococcal vaccine and its implications for use in adults in developed countries. Hum Vaccin Immunother. 2014; 10(5):1331-3.
Score: 0.415
-
The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence? Clin Infect Dis. 2011 Mar 01; 52(5):633-40.
Score: 0.333
-
V(H)3 antibody response to immunization with pneumococcal polysaccharide vaccine in middle-aged and elderly persons. Clin Vaccine Immunol. 2011 Mar; 18(3):362-6.
Score: 0.330
-
Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis. 2008 Oct 01; 198(7):1019-27.
Score: 0.282
-
Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study. Clin Infect Dis. 2008 Apr 01; 46(7):1093-100.
Score: 0.272
-
Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia. Clin Infect Dis. 2006 Oct 15; 43(8):1004-8.
Score: 0.244
-
Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis. 2003 Aug 01; 37(3):438-47.
Score: 0.197
-
Protease Inhibitors Do Not Affect Antibody Responses to Pneumococcal Vaccination. Clin Vaccine Immunol. 2016 06; 23(6):524-529.
Score: 0.120
-
Qualitative change in antibody responses of human immunodeficiency virus-infected individuals to pneumococcal capsular polysaccharide vaccination associated with highly active antiretroviral therapy. J Infect Dis. 2003 Mar 01; 187(5):758-68.
Score: 0.048
-
IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-infected subjects: persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response. J Infect Dis. 1996 Jun; 173(6):1347-53.
Score: 0.030
-
Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. J Infect Dis. 1992 Mar; 165(3):553-6.
Score: 0.022
-
Human antibodies elicited by a pneumococcal vaccine express idiotypic determinants indicative of V(H)3 gene segment usage. J Infect Dis. 1998 Sep; 178(3):707-16.
Score: 0.009
-
Genetic regulation of the capacity to make immunoglobulin G to pneumococcal capsular polysaccharides. J Investig Med. 1997 Feb; 45(2):57-68.
Score: 0.008
-
Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. J Infect Dis. 1996 Jan; 173(1):83-90.
Score: 0.007